Rani Therapeutics Holdings (RANI) Interest Coverage Ratio (2020 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly Interest Coverage Ratio came in at 3.44 in Q1 2026, up 73.03% year-on-year from 1.99 in Q1 2025, and up 80.84% quarter-over-quarter from 17.93 in Q4 2025.
Rani Therapeutics Holdings (RANI) Interest Coverage Ratio (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Interest Coverage Ratio history runs 7 years deep, the most recent figure standing at 3.44 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 73.03% year-over-year to 3.44 in Q1 2026; TTM through Mar 2026 was 14.27, a 88.16% decrease from a year earlier, with the FY2025 full-year figure at 0.48, up 95.43% from the prior year.
- Interest Coverage Ratio improved to 3.44 in Q1 2026 per RANI's latest filing, from 17.93 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 1.52 in Q3 2025 and bottomed at 46.25 in Q4 2022.
- The 5-year median for Interest Coverage Ratio is 12.74 (2025), against an average of 12.89.
- Across the five-year window, Interest Coverage Ratio slumped 1068.49% in 2022 and soared 91.46% in 2023, its largest moves.
- Year by year, Interest Coverage Ratio stood at 46.25 in 2022, then surged by 91.46% to 3.95 in 2023, then plunged by 237.0% to 13.31 in 2024, then sank by 34.74% to 17.93 in 2025, then surged by 80.84% to 3.44 in 2026.
- Per Business Quant, the three latest RANI Interest Coverage Ratio figures stand at 3.44 (Q1 2026), 17.93 (Q4 2025), and 1.52 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Rani Therapeutics Holdings | 160.20 Mn | 167.33 Mn | - | -3.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.44 |
| Dec 31, 2025 | -17.93 |
| Sep 30, 2025 | -1.52 |
| Jun 30, 2025 | -11.07 |
| Mar 31, 2025 | -12.74 |
| Dec 31, 2024 | -13.31 |
| Sep 30, 2024 | -1.77 |
| Jun 30, 2024 | -9.10 |
| Mar 31, 2024 | -10.85 |
| Dec 31, 2023 | -3.95 |
| Sep 30, 2023 | -13.57 |
| Jun 30, 2023 | -14.38 |
| Mar 31, 2023 | -13.68 |
| Dec 31, 2022 | -46.25 |
| Sep 30, 2022 | -28.47 |
| Jun 30, 2022 | -14.69 |
| Mar 31, 2022 | -2.43 |
| Dec 31, 2021 | 73.42 |
| Sep 30, 2021 | -2.44 |
| Jun 30, 2021 | -31.11 |